Literature DB >> 22552893

Extensively drug-resistant Pseudomonas aeruginosa: risk of bloodstream infection in hospitalized patients.

C Peña1, S Gómez-Zorrilla, C Suarez, M A Dominguez, F Tubau, O Arch, A Oliver, M Pujol, J Ariza.   

Abstract

Several studies have suggested that resistance determinants usually reduce virulence. However, their contribution to decrease bloodstream infections is unclear. Our aim was to identify risk factors of extensively drug-resistant (XDR) Pseudomonas aeruginosa (PA) bacteremia and to assess the prevalence of XDR-PA bacteremia. A retrospective study of PA bloodstream infections in our patient population with at least one clinical sample isolate due to PA (2006-2007) was carried out. A total of 2,131 patients with PA clinical samples were detected. Among 1,657 patients with susceptible-PA isolates, 95 developed PA-susceptible bacteremia. Concomitantly, among 474 patients with multidrug-resistant (MDR)-PA isolates, 265 with XDR-PA, and 209 with non-XDR MDR-PA, 43 developed XDR-PA bacteremia and 13 non-XDR MDR-PA bacteremia, respectively. Pulsed-field gel electrophoresis (PFGE) revealed the clonal nature of the two predominant XDR-PA phenotypes and genetic heterogeneity in non-XDR MDR-PA phenotypes. The proportion of XDR-PA bacteremia was higher than the proportion of bacteremia in the susceptible-PA population (16 % vs. 6 %; p < 0.001). A logistic regression model identified prior exposure to fluoroquinolones [odds ratio (OR) 2.80; 95 % confidence interval (CI) 1.02 to 7.70] as the independent variable associated with XDR-PA bacteremia. Our study suggests that XDR-PA strains have a greater ability to develop bacteremia. It remains unclear as to whether this invasive capacity depends on clonal traits or on other virulence determinants.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22552893     DOI: 10.1007/s10096-012-1629-3

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  28 in total

1.  Effect of antibiotic therapy on the density of vancomycin-resistant enterococci in the stool of colonized patients.

Authors:  C J Donskey; T K Chowdhry; M T Hecker; C K Hoyen; J A Hanrahan; A M Hujer; R A Hutton-Thomas; C C Whalen; R A Bonomo; L B Rice
Journal:  N Engl J Med       Date:  2000-12-28       Impact factor: 91.245

2.  Multidrug-resistant Pseudomonas aeruginosa: risk factors and clinical impact.

Authors:  Valerie Aloush; Shiri Navon-Venezia; Yardena Seigman-Igra; Shaltiel Cabili; Yehuda Carmeli
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

3.  A step closer to extreme drug resistance (XDR) in gram-negative bacilli.

Authors:  David L Paterson; Yohei Doi
Journal:  Clin Infect Dis       Date:  2007-09-27       Impact factor: 9.079

4.  Epidemiology and clinical outcomes of patients with multiresistant Pseudomonas aeruginosa.

Authors:  A Harris; C Torres-Viera; L Venkataraman; P DeGirolami; M Samore; Y Carmeli
Journal:  Clin Infect Dis       Date:  1999-05       Impact factor: 9.079

5.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.

Authors:  M E Charlson; P Pompei; K L Ales; C R MacKenzie
Journal:  J Chronic Dis       Date:  1987

Review 6.  Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing.

Authors:  F C Tenover; R D Arbeit; R V Goering; P A Mickelsen; B E Murray; D H Persing; B Swaminathan
Journal:  J Clin Microbiol       Date:  1995-09       Impact factor: 5.948

7.  Imipenem-resistant Pseudomonas aeruginosa: risk factors and antibiotic susceptibility patterns.

Authors:  N Troillet; M H Samore; Y Carmeli
Journal:  Clin Infect Dis       Date:  1997-11       Impact factor: 9.079

8.  Emergence of antibiotic-resistant Pseudomonas aeruginosa: comparison of risks associated with different antipseudomonal agents.

Authors:  Y Carmeli; N Troillet; G M Eliopoulos; M H Samore
Journal:  Antimicrob Agents Chemother       Date:  1999-06       Impact factor: 5.191

9.  Risk factors for imipenem-resistant Pseudomonas aeruginosa among hospitalized patients.

Authors:  Anthony D Harris; David Smith; Judith A Johnson; Douglas D Bradham; Mary-Claire Roghmann
Journal:  Clin Infect Dis       Date:  2001-12-26       Impact factor: 9.079

10.  Nosocomial outbreak of a non-cefepime-susceptible ceftazidime-susceptible Pseudomonas aeruginosa strain overexpressing MexXY-OprM and producing an integron-borne PSE-1 betta-lactamase.

Authors:  C Peña; C Suarez; F Tubau; C Juan; B Moya; M A Dominguez; A Oliver; M Pujol; J Ariza
Journal:  J Clin Microbiol       Date:  2009-06-03       Impact factor: 5.948

View more
  11 in total

1.  Prospective observational study of prior rectal colonization status as a predictor for subsequent development of Pseudomonas aeruginosa clinical infections.

Authors:  Silvia Gómez-Zorrilla; Mariana Camoez; Fe Tubau; Rosario Cañizares; Elisabet Periche; M Angeles Dominguez; Javier Ariza; Carmen Peña
Journal:  Antimicrob Agents Chemother       Date:  2015-06-15       Impact factor: 5.191

2.  The prophylactic effects of human IgG derived from sera containing high anti-PcrV titers against pneumonia-causing Pseudomonas aeruginosa.

Authors:  Mao Kinoshita; Hideya Kato; Hiroaki Yasumoto; Masaru Shimizu; Saeko Hamaoka; Yoshifumi Naito; Koichi Akiyama; Kiyoshi Moriyama; Teiji Sawa
Journal:  Hum Vaccin Immunother       Date:  2016-07-25       Impact factor: 3.452

Review 3.  New Insight on Epidemiology and Management of Bacterial Bloodstream Infection in Patients with Hematological Malignancies.

Authors:  Sara Lo Menzo; Giulia la Martire; Giancarlo Ceccarelli; Mario Venditti
Journal:  Mediterr J Hematol Infect Dis       Date:  2015-07-01       Impact factor: 2.576

4.  Complete Genome Sequence of the Myoviral Bacteriophage YS35, Which Causes the Lysis of a Multidrug-Resistant Pseudomonas aeruginosa Strain.

Authors:  Sheng Yu; Honglan Huang; Yuchong Hao; Hongyan Shi; Chunyan Zhao; Yanbo Sun
Journal:  Genome Announc       Date:  2018-02-08

5.  Multi-locus sequence typing (MLST) of non-fermentative Gram-negative bacilli isolated from bloodstream infections in southern Poland.

Authors:  Agnieszka Chmielarczyk; Monika Pobiega; Dorota Romaniszyn; Jadwiga Wójkowska-Mach
Journal:  Folia Microbiol (Praha)       Date:  2017-09-22       Impact factor: 2.099

6.  Drug Resistance of Pseudomonas aeruginosa and Enterobacter cloacae Isolated from ICU, Babol, Northern Iran.

Authors:  Masoomeh Bayani; Sepideh Siadati; Ramzan Rajabnia; Ali Asghar Taher
Journal:  Int J Mol Cell Med       Date:  2013

7.  An outbreak of extremely drug-resistant Pseudomonas aeruginosa in a tertiary care pediatric hospital in Italy.

Authors:  Marta Ciofi Degli Atti; Paola Bernaschi; Michaela Carletti; Ida Luzzi; Aurora García-Fernández; Alice Bertaina; Annamaria Sisto; Franco Locatelli; Massimiliano Raponi
Journal:  BMC Infect Dis       Date:  2014-09-10       Impact factor: 3.090

8.  Clinical and treatment-related risk factors for nosocomial colonisation with extensively drug-resistant Pseudomonas aeruginosa in a haematological patient population: a matched case control study.

Authors:  Matthias Willmann; Anna M Klimek; Wichard Vogel; Jan Liese; Matthias Marschal; Ingo B Autenrieth; Silke Peter; Michael Buhl
Journal:  BMC Infect Dis       Date:  2014-12-10       Impact factor: 3.090

9.  Epidemiology and risk factors of extensively drug-resistant Pseudomonas aeruginosa infections.

Authors:  Nattawan Palavutitotai; Anupop Jitmuang; Sasima Tongsai; Pattarachai Kiratisin; Nasikarn Angkasekwinai
Journal:  PLoS One       Date:  2018-02-22       Impact factor: 3.240

10.  Risk factors for hospitalized patients with resistant or multidrug-resistant Pseudomonas aeruginosa infections: a systematic review and meta-analysis.

Authors:  Gowri Raman; Esther E Avendano; Jeffrey Chan; Sanjay Merchant; Laura Puzniak
Journal:  Antimicrob Resist Infect Control       Date:  2018-07-04       Impact factor: 4.887

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.